Recent CRIS News
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 02/12/2024 09:16:14 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 02/08/2024 09:36:50 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 02/08/2024 09:27:47 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/08/2024 09:01:17 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/08/2024 01:01:02 PM
- Curis Provides Fourth Quarter 2023 Business Update • PR Newswire (US) • 02/08/2024 01:00:00 PM
- Curis to Release Fourth Quarter 2023 Financial Results and Hold Conference Call on February 8, 2024 • PR Newswire (US) • 02/01/2024 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/11/2024 01:13:35 PM
- Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) • PR Newswire (US) • 01/05/2024 01:00:00 PM
- Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend] • Edgar (US Regulatory) • 12/21/2023 09:00:47 PM
- Curis Announces Initial Combination Study Data from its TakeAim Lymphoma Study • PR Newswire (US) • 12/12/2023 01:00:00 PM
- Curis Presented Clinical Data from the TakeAim Leukemia Study at the 2023 ASH Conference • PR Newswire (US) • 12/11/2023 01:00:00 PM
- Curis Announces Three Presentations at ASH • PR Newswire (US) • 12/06/2023 01:00:00 PM
- Curis Enters into Agreement for Emavusertib / Pembrolizumab Combination Study in Melanoma • PR Newswire (US) • 12/05/2023 01:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/02/2023 12:03:50 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/02/2023 12:01:51 PM
- Curis Provides Third Quarter 2023 Business Update • PR Newswire (US) • 11/02/2023 12:00:00 PM
- Curis to Release Third Quarter 2023 Financial Results and Hold Conference Call on November 2, 2023 • PR Newswire (US) • 10/26/2023 12:30:00 PM
- Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) • PR Newswire (US) • 10/06/2023 12:56:00 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 09/28/2023 08:05:45 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/28/2023 12:54:37 PM
- Curis Announces Date for the 2nd Symposium on IRAK4 in Cancer • PR Newswire (US) • 09/12/2023 12:00:00 PM
- Curis to Present at Upcoming Healthcare Conferences in September • PR Newswire (US) • 09/06/2023 12:13:00 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 08/18/2023 08:02:24 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 08/04/2023 08:09:04 PM
Endexx Corporation (EDXC) Leverages Global Market Trends and Legislative Reforms to Spearhead Growth in the Cannabis and Plant-Based Wellness Sectors • EDXC • Mar 27, 2024 3:01 PM
Applied UV, Inc. Announces Pricing of $2.76 Million Registered Direct and Private Placement Priced at the Market Under Nasdaq Rules • AUVI • Mar 27, 2024 2:51 PM
POET and MultiLane Collaborate to Develop High-Speed Pluggable Transceivers for AI Networks • POET • Mar 27, 2024 10:52 AM
Maybacks Global Entertainment Opens 23 More Stations in Important Major Cities • AHRO • Mar 27, 2024 9:00 AM
NxGen Brands Inc. Forecast to Deliver 140% Growth in Q1 2024 • NXGB • Mar 27, 2024 7:30 AM
Kona Gold Beverages, Inc. Strategic Advancements: Covert LLC Introduces Federally Legal D9 Gummies and Revamps Innovative eCommerce Platform, Propelling Toward $12 Million Annual Revenue Goal • KGKG • Mar 26, 2024 8:30 AM